The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I think this is still well cheap.
15p before buys, I expect this to go up.
Sticky fingers. Way to cheap, imo.
5p at a 20:1 consolation is £1. That would seem to be the bottom that KLK would want.
Regardless of all that though the market cap will look like peanuts compared to comparable mining companies.
From what I read and heard these shares are being held tightly and you can expect this to rise.
I had to be that guy, now in the unlikely event I will be right haha! And I will act like I knew something.
Nearer to a £1 than 15p one would hope. If not then I will most likely buy more.
I don't really follow the examples of risk.
Any business follows a core structure.
Retail - have retail outlets
Travel providers - have planes
There must be as a core to any business.
If nuvec doesnt work it... Then so be it, that's the way of the land. They wouldn't be 100 miles off as like everything it follows a basic outline of something prior. It's called innovation, if someone never tries we will never know.
I don't think it's so much the sentiment, there is no current timeline on news. Therefore it will not move till then.
So people will be shifting there money else where to make a quick buck. EG. 4D Pharma.
Personally i cannot be bothered with that, news can land at anytime i'm not going to rebuy in at a higher point.
I very much believe that Pfizer will be interest in the delivery that N4P can provide. At the moment you like the likes of AstraZeneca, they are not doing it for profit nore do you need the same storage facilities. Vaccine alone i think AstraZeneca is $20 cheaper per vaccine, not even including the storage demands required. Their best fighting chance for more market share and larger profits is to improve the delivery.
Regarding share loss in the tax year the shares would need need to be disposed. This might be the most difficult bit as no one really knows what's going on, if you were to offset prematurely me something eventually happens with the share that could cause some questions to arise.
Regarding its value it will be the initial starting value, the container in which the shares sat in (ISA) you wouldn't be able to offset theoretical profits.
My Inital thoughts is that we probably wont hear much until March 2021, most companies would normally want to have a year worth of a cashflow plan. Also be interesting who owns the other 48.6% of Capital Metals Limited, assume its the orginal holders and their families, a bit of skin in the game is always good.
The Directors have prepared a cash flow forecast for the period ending 31 March 2022, which considers the cash held by the Group at the year end, less future administrative and planned expenditure.
The forecasts do not assume that additional cash will be raised by the Company or that the CML transaction will complete. These forecasts show that the Company currently has sufficient cash to pay the overheads of a cash shell throughout the forecast period.
On 21 October 2020, the Company announced that it has reached conditional agreement with parties holding a majority of the shares (51.4 per cent.) ("CML Majority") of Capital Metals Limited ("CML"), a company developing a high grade mineral sands project in Sri Lanka, to acquire their shares in CML ("CML Shares") in exchange for ordinary shares in the Company ("Ordinary Shares").
If you read between the lines, they mentioned new vaccines. I think we all know what they are.
Wouldn't suprise me if they got called out by Pfizer and they said will prove it, this being the product focused experiments?
"Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines"
"Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaborations."
Read it
"With this in mind and taken together with previous positive data, the Company has decided to proceed to a full in vivo study to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies."
Do not see an issue.
"There will obviously be left overs from rounding. Not sure on what happens to those."
roundings would be like a quid, it just disappears and investors lose it
Realistically it's a pretty standard request, sort out your company mess before enriching yourself and your shareholders.
Seems completely fair to me.
"restoring confidence in its corporate governance and building a sustainable business for the long term."
No fear of it collapsing etc, FCA said long term.
If share holders have no ownership then nor does zaza or Steve. So I think you will find the pie will end up being shared. The shares are held at highest point of the corporation, so an subsidiaries are part of our ownership.
You would think it would have to mean 5p+